INTRODUCTION
Transferrin receptor-2 (TFR2) is a type II transmembrane glycoprotein homologous to TFR1(1), able to bind diferric-transferrin (holo-TF), although with lower affinity than TFR1. In iron homeostasis TFR2 appears to have regulatory rather than transport functions, since TFR2 mutations in humans (2) and Tfr2 inactivation in mice(3),(4), (5) cause iron overload with low hepcidin (6) .
TFR2 is mainly expressed in the liver (1) , (7) where it is essential for hepcidin control. Its expression is up-regulated during hepatic development but is not modulated by iron; indeed TFR2 mRNA has no detectable iron-responsive elements in its untranslated regions (8) .
TFR2 encodes an 801 amino acids protein with a short cytosolic tail that contains a potential internalization signal, a transmembrane domain and a large C-terminal ectodomain. The latter has a protease-associated domain, a peptidase M28 like and a dimerization domain with two RGD motifs, important for protein-protein interaction and for transferrin binding. Mutations of TFR2 cause type 3 hemochromatosis: all reported mutations(2) are rare, often private. Mutations are loss of function including frameshift, premature stop, small deletions and missense mutations prevalently affecting the protein C-terminus, especially the peptidase-like and the dimerization domains (9) .
Binding to holo-TF stabilizes TFR2 on cell surface (10) and this interaction redirects TFR2 towards the recycling instead of the lysosomal degradation pathway (4) . Experiments in cultured hepatoma cell lines suggest that TFR2, bound to holo-TF, may simultaneously bind HFE. While the HFE-and the TF-binding sites on TFR1 overlap, in TFR2 they are different (10) , (11) . The HFE-TFR2 complex has been proposed to act as a sensor of circulating iron and as an activator of hepcidin expression (12) . However, recent data suggest that the two proteins may have separate functions and also their interaction is controversial (13) . Iron overload is more severe in Tfr2 −/− than in Hfe −/− mice and Tfr2-Hfe double knock out mice show the most severe disease (14) . Studies in patients indicate that TFR2 plays a prominent and HFE a minor role in hepcidin activation in response to acute increase of transferrin saturation after a single dose of oral iron (15) . As a further level of complexity TFR2 gene, which shows two consensus sequences for the erythroid transcription factor GATA-1 in its promoter (12) , is expressed in immature erythroid cells (16) where it is a component of the erythropoietin receptor (EPOR) complex (17) . The TFR2-EPOR association is required for the efficient transport of EPOR to the cell surface. Although both TFR2-hemochromatosis patients and Tfr2 −/− mice have no evident hematologic abnormalities, the erythroid progenitors from Tfr2 −/− young mice appear less sensitive to erythropoietin (EPO) and have increased serum Epo levels.
Moreover, TFR2 silencing in human erythroid progenitors delays their terminal differentiation (17) .
TFR1 sheds a soluble counterpart (sTFR1), in vitro and in vivo, that is measurable in serum from normal individuals (18) . TFR1 is highly expressed on the surface of maturing erythroblasts and, when unbound to holo-TF, is released into plasma in high concentration. This process occurs in iron deficiency anemia, in erythropoiesis expansion and in some hematologic malignancies (19) . On the contrary sTFR1 levels are reduced in aplastic and hypoproliferative anemias. Although its function remains unexplained, sTFR1 has been proposed as a marker of iron deficiency and/or of total erythropoietic activity. The shedding of sTFR1 is regulated by its ligand holo-TF and, as recently shown, is mediated by the proprotein convertase subtilisin/kexin type 7 (PCSK7) (20) . Interestingly, PCSK7 genetic variants are associated with sTFR1 quantitative trait in genome wide association studies (21) .
Here we characterize a previously unrecognized soluble form of TFR2 (sTFR2) that is shed from plasma membrane both in transfected cell lines and in TFR2-expressing erythroid cells. We show that the process of TFR2 release is regulated by the ligand holo-TF, a regulation lost in a TFR2 mutant (TFR2   G679A   ) , unable to bind the ligand. Because of its low affinity for holo-TF, we suggest that the shedding of TFR2 signals iron deficiency simultaneously in hepatic and erythroid cells.
METHODS

Wild type and mutant constructs
A TFR2 wild type cDNA was cloned in pCMV-TAG4 vector with a FLAG-tag at the C-terminus (TFR2 WT-C-FLAG ). TFR2 wild type (TFR2 WT-N-FLAG ) and TFR2 G679A constructs in pcDNA3.1(+) have a FLAG-tag at the N-terminus. A "soluble" artificial isoform of TFR2 (sTFR2*) was generated by amplification of the coding region from nucleotide 313 (Arg105) to nucleotide 2403 (Phe801) and in frame-cloned in pSEC-TAG (B), with a MYC-HIS-tag at C-terminus, using the following oligonucleotides:
sTFR2-KpnI-fw: 5'-GGGGTACCCGAGGGTCCTGCCAGGCG-3' sTFR2-EcoRI-rev: 5'-GGAATTCCAGAAGTTGTTATCAATGTTCC-3'
Mammalian expressing vectors encoding for wild type dynamin (Dyn WT ) and the dominant negative variant Dyn K44A were described in (22) . HJV expressing vector and the hepcidin promoter luciferase reporter construct (Hep-Luc) were as described (23) . FURIN and PCSK7 expressing vectors were described in Supplemental Methods
Cell culture and reagents
HeLa, HEK293, CHO-Trvb-0, the erythroleukemic cell line UT7 and the hepatoma cell lines HuH7 When indicated, cells were treated with different concentrations (0.5, 1.25, 5 and 25μM) of human or bovine diferric-transferrin (H-holo-TF and B-holo-TF, respectively) and human apo-transferrin (apo-TF) (Sigma-Aldrich, St. Louis, MO) in serum-free media; erythroid cells were treated with 25μM of human apo-or holo-TF.
Brefeldin-A (BFA, Sigma-Aldrich), a fungal antibiotic that alters the intracellular trafficking by blocking protein maturation across the post-ER compartment, was used at 100-500 ng/mL.
Procedures for pull-down of membrane and soluble TFR2, western blot analysis of conditioned cell culture media and total cell lysates, luciferase reporter assay for sTFR2 effect on hepcidin promoter are described in Supplemental Methods.
Scatchard analysis
UT-7 cells were suspended in binding medium (alpha-MEM containing 20 mM Hepes, 10% FCS, 0.1% sodium azide, pH 7.2). Twenty-five μl of the cell suspension, containing 4x10 6 cells, were incubated with 25 μl of conditioned medium from HEK293 cells transfected with the empty or sTFR2* expressing vectors. Samples were equilibrated at 37°C for 60 min. Twenty-five μl of binding medium alone or 25 μl of a 100-fold excess of unlabeled EPO were added to the binding assay. Then the chosen amount of 125 I-EPO, in a volume of 25 μl was added, and cells were further incubated for 30 min at 37°C. The content of each well was carefully layered over 900 µl of a cold solution of PBS and centrifuged at 4°C for 10 min at 600 g. Unbound radioactivity was counted and after 3 washes in PBS, cell-bound radioactivity was counted in the pellet. The non-specific binding of 125 I-EPO determined by adding a 100-fold excess of unlabeled EPO to the binding assay was subtracted from the total binding to give the specific binding.
Two independent experiments have been performed using two different batches of 125 I-EPO and control conditioned medium or sTFR2*-containing conditioned medium from two independent experiments.
RESULTS
Identification of a soluble form of TFR2 (sTFR2)
To study the cell localization and processing of TFR2, HeLa cells, which do not express endogenous TFR2 (data not shown), were transiently transfected with an expressing vector that encodes for a N-FLAG tagged form of TFR2 (TFR2 WT-N-FLAG ). Since TFR1 and other iron-related proteins present on cell membrane release soluble forms, we investigated whether this would also occur with TFR2. In the media of TFR2 transfected cells we identified a single band (sTFR2) of about 80 kDa, which migrated faster than the cell-associated isoforms, suggesting that it was the result of a cleavage mechanism. Since sTFR2 can be detected using the anti-TFR2 antibody, recognizing residues from amino acid 150 to 250, but not with the anti-FLAG antibody when using an N-terminal flagged construct, we concluded that the cleavage occurs at the N-terminal part of the protein, close to the transmembrane domain, as occurs for sTFR1 (24) . To further confirm this finding, sTFR2 from cells transfected with TFR2 WT-C-FLAG that has a FLAG-tag at the C-terminus, 
sTFR2 is shed from plasma membrane
It was previously reported that the receptor exposed on the cell surface is stabilized in the presence of holo-TF with a maximum effect at 25 µM holo-TF(10). We confirmed the same stabilization both in transfected cells and in TFR2-competent cells. HeLa cells transfected with TFR2
WT-C-FLAG construct were treated with human holo-and apo-TF (25 μM) in serum-free media and were biotinylated to label membrane proteins. sTFR2 was pulled-down using anti-FLAG Sepharosebeads to avoid holo-TF interference with gel migration of concentrated culture media. In these conditions, as a consequence of holo-TF treatment, we observed a reduction of sTFR2 mirrored by an increase in membrane exposed TFR2 (Figure 2A) .
A substantial increase in the expression of membrane TFR2 was also detected in biotinylated plasma membranes from erythroid UT7 cells and primary erythroblasts when cultured in the presence of holo-TF, while endogenous sTFR2 production was decreased ( Figure 2B ). This confirms that the inverse regulation of membrane and sTFR2 in the presence of the ligand is maintained also in cells expressing endogenous TFR2 (Figure 2A) .
We asked whether sTFR2 originates from plasma membrane or is released during receptor internalization. To this aim cell surface proteins were labelled using a cell-impermeable biotin and were treated with holo-TF. sTFR2 was detected in the culture media of transfected cells after streptavidin pull down of biotin-labelled proteins, demonstrating that it originates from membrane exposed TFR2 ( Figure S1B ).
To further prove the membrane origin of sTFR2, we treated HeLa cells with brefeldin-A (BFA), a fungal antibiotic that alters the intracellular trafficking by blocking protein maturation across the post-ER compartment (25) . BFA induced a strong reduction of both membrane-associated and sTFR2 ( Figure 2C) , consistent with the finding that TFR2 is shed from the cell surface.
To investigate the potential contribution of endocytosis in the release of sTFR2, we exploited the effect of dynamin dead-mutant K44A (Dyn
K44A
) that blocks the endocytosis process, thus "fixing" the proteins on cell surface (26) . The amount of sTFR2 in cells transfected with Dyn K44A was strongly increased compared to that of cells transfected with wild type dynamin (Dyn WT ), further strengthening that the cleavage occurs at the cell surface ( Figure 2D ). Under these conditions, holo-TF was still able to reduce the shedding process ( Figure 2E ).
TFR2 shedding is inhibited by holo-transferrin in a dose dependent manner
TFR2 can bind holo-TF and is highly homologous to TFR1 and the release of sTFR1 is reduced by its ligand (27) . For these reasons we investigated whether sTFR2 release was affected by holo-TF in our in vitro system. HuH7 ( Figure 3A) and HeLa (Figure S1B-C) cells were transiently transfected with the TFR2 expressing vector and then treated with increasing concentrations of human holo-TF.
To avoid holo-TF interference with gel migration of concentrated culture media, we biotinylated cell surface proteins and pulled-down sTFR2 in the supernatants using streptavidin beads. As shown in Figure 3A , human holo-TF inhibited the release of sTFR2 in a dose-dependent manner.
This inhibition was not mediated by iron, since treatment of TFR2 transfected cells with iron donors (FAC) or iron chelators (DFO) did not modulate sTFR2 concentration in the culture media ( Figure   S1A ).
To understand whether the observed inhibition was a direct effect of the ligand binding, we used the
, an artificial variant unable to bind holo-TF since the mutation inactivates the RGD binding domain (28) . As shown in Figure 3B , TFR2 G679A released sTFR2 in high concentration and the process was not modulated by the ligand.
Shedding of TFR2 occurs independently of TFR1
To exclude that sTFR2 release might be influenced by binding of holo-TF to its high affinity receptor TFR1 we used two approaches. First, we used bovine holo-TF that specifically binds TFR2, while is unable to bind human TFR1 (28) . As with human holo-TF, sTFR2 was strongly decreased in the presence of bovine holo-TF both in HeLa ( Figure 4A ) and in HuH7 cells (not shown). Second, we analysed the shedding process in TFR2 transfected CHO-Trvb-0 cells that lack TFR1 (29) . We confirmed that these cells did not express TFR1 ( Figure S2 ) and we showed that also in these cells holo-TF inhibited the release of sTFR2 and stabilized TFR2 on cell surface ( Figure 4B ).
Overall our results demonstrate that the shedding of TFR2 does not require TFR1 and that the inhibition of sTFR2 release directly results from ligand-receptor binding.
sTFR2 does not affect EPOR expression or EPO binding in erythroid cells and mildly reduces hepcidin promoter activation in hepatoma cells
Because TFR2-EPOR association is required for the efficient transport of EPOR to the cell surface(17), we studied whether sTFR2 could modify the number of cell surface EPOR or the affinity of EPO for its receptor by Scatchard analysis in UT7 cells. To investigate this issue, we used sTFR2* that is functional (see below) and more efficiently produced than the naturally cleaved TFR2 ( Figure 1A) . The conditioned medium of HEK293 cells transfected with sTFR2* (Sn sTFR2*) or with empty vector (Sn mock) did not modify significantly the number of EPOR expressed on cell surface nor the affinity for its ligand ( Figure 5A ). However, BFA treatment decreased the number of EPOR on the plasma membrane ( Figure S3 ). To investigate the activation of the EPO-mediated intracellular signalling, the phosphorylation status of STAT5, AKT and ERK, major targets of this pathway, was assessed in UT7 cells treated or not with sTFR2*. As shown in
Figure 5B and quantitated in Figure 5C , the EPO signalling was not significantly affected by sTFR2*. These data were supported by the observation that exogenous sTFR2* did not interact with the EPOR when added to the culture medium ( Figure S4 ).
To evaluate the functional role of sTFR2 in hepatic compartment, we studied the modulation of the hepcidin promoter in HuH7 cells, treated with the conditioned medium of the same hepatoma- To analyse whether sTFR2 could interfere with BMPs signalling we studied the response of the hepcidin promoter in Hep3B cells in presence of both sTFR2* and BMP6 and we confirmed the same partial inhibitory effect observed both in basal and in HJV-mediated hepcidin activation ( Figure S5D) . However, an effect of sTFR2 was observed only in vitro on the hepcidin promoter assay.
DISCUSSION
From its discovery more than 10 years ago(1) and its identification as the gene responsible of hemochromatosis type 3(2), the function of the second transferrin receptor (TFR2) has remained obscure. The role of TFR2 as a component of the liver iron-sensing machinery and hepcidin activator is well established, but the molecular mechanisms remain unravelled. The role of TFR2 as partner of EPOR in immature erythroid cells has been clearly defined, and our recent results have shown that it negatively controls erythropoiesis expansion in iron deficiency (30) .
In this paper we expand our knowledge on the structure of this receptor, identifying its soluble form (sTFR2). sTFR2 was detected in the medium of different cell lines transfected with TFR2 and most importantly was present in the culture media of both erythroid cell lines and primary human erythroid cells that endogenously express TFR2 (16), (17) .
We show that sTFR2 is shed from the membrane-exposed receptor. This conclusion is supported by two lines of evidence: 1) the lack of sTFR2 shedding when the receptor does not reach the cell surface, as after BFA treatment; 2) the increase of sTFR2 release in the opposite condition, when the receptor is stabilized on the membrane by a mutant dynamin.
TFR2 associates with different partners (EPOR in erythroid cells, HJV and HFE in the liver) and
has likely different functions in the two tissues where is highly expressed. However, the shedding mechanism appears to be under a common iron-mediated regulation. Indeed binding of the holo-TF ligand to the receptor inhibits sTFR2 release, while in the absence of the ligand binding the release is increased both in hepatoma and in erythroid cells, providing a common iron sensing mechanism.
Holo-TF binds to the RGD motif in the TFR2 ectodomain. Importantly, the RGD mutant TFR2 G679A , unable to bind the ligand (28) , is insensitive to the shedding regulation. This phenomenon clearly indicates that the shedding process is directly controlled by the receptor-ligand molecular interaction and, as previously reported for TFR1, couples the TFR2 shedding process with iron deficiency. However, the release of TFR2 does not require TFR1. It is reasonable that the shedding of the two receptors occurs separately, since their expression is maximal at different maturation stages of the erythroid cells, TFR2 being expressed in more immature erythroid precursors than TFR1 (16) , (17) . Also in the liver Tfr2 expression increases during mouse development in parallel with the decrease of Tfr1 expression (8) . Furthermore, the cleavage of the two receptors is likely operated by different proteases. The consensus cleavage site for PCSK7, the proconvertase that cleaves TFR1, is not conserved in TFR2 ( Figure S6 ). The observed inhibition of TFR2 shedding by the proconvertase inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone (CMK) indicates that a furin-like proconvertase operates the cleavage. However, both furin and PCSK7, the proteases involved in sHJV(31) and sTFR1 (20) cleavage are not involved in TFR2
shedding ( Figure S6) . Overall, our results indicate that removal of TFR2 from cell surface is not only due to lack of receptor stabilization, but is dependent on an active cleavage process. It is conceivable that membrane stabilization of TFR2 by holo-TF subtracts the receptor to the protease activity by changing its conformation or by hiding the cleavage site. The definition of these molecular mechanisms requires further studies. We cannot exclude that, as previously reported (4), also a decreased endocytosis and TFR2 lysosomal degradation might occur in addition to the reduced shedding in the presence of the ligand.
Different proteins and receptors acquire a distinct function when present either as membrane-bound or soluble forms, as shown for HJV (32) , (33), (31) . We cannot exclude a dual and opposite role also in case of TFR2. Sensing the increased concentration of the ligand, membrane TFR2 is proposed to be involved in hepcidin activation to reduce the levels of circulating iron (12) . Its soluble counterpart might act as an inhibitor to attenuate the signalling pathway, in conditions of reduced iron availability, to increase iron absorption. We consistently showed a modest inhibition of hepcidin promoter activation by sTFR2, but not of endogenous hepcidin in hepatic cell lines (not shown). In addition when iron deficiency is induced in the double knock out Tfr2-/-, Tmprss6 -/-mice hepcidin is inhibited ruling our a significant contribution of sTfr2, that cannot be produced in these animals (34) . Thus the decoy function on hepcidin activation is unlikely. However, irrespective of sTFR2 function, removal of membrane TFR2 in iron deficiency would negatively affect hepcidin activation.
An erythroid role for Tfr2 in conditions of low iron has been recently suggested by the observation that iron deficiency caused by ablation of the hepcidin inhibitor Tmprss6 induces erythrocytosis in mice knock out for Tfr2, but not in mice with liver specific Tfr2 deletion (that preserves the Tfr2 erythroid function (34) . This event was directly confirmed by the increased erythropoiesis observed in mice that had Tfr2 exclusively deleted in the bone marrow (30).
sTFR2 added as culture media of transfected cells does not seem to modify the affinity of EPO for EPOR or the cell surface expression of the EPOR. Consequently the EPO-mediated signalling appears not to be affected. Preliminary experiments show that the addition of sTFR2 to the culture medium of primary human erythroblasts does not affect their proliferation, survival and terminal differentiation (data not shown). However, irrespective of sTFR2 function, shedding membrane TFR2 in iron deficiency might serve to decrease its interaction with EPOR and to increased EPO sensitivity of erythroid cells, as recently shown in mice with bone marrow specific Tfr2 deletion (30) . The lower affinity for holo-TF as compared with TFR1 makes TFR2 an ideal sensor of iron deficiency in the bone marrow that could anticipate the iron needs for maturing erythroblasts. It is possible that when holo-TF concentration starts decreasing, TFR2 would be shed from the membrane, whereas TFR1, because of its higher affinity, would still be able to bind holo-TF.
In conclusion we provide in vitro evidence of TFR2 shedding, a mechanism regulated by holo-TF, in analogy with the process described for TFR1. Although the in vivo role of sTFR2, as well as that of sTFR1, remains to be clarified, we suggest that while membrane TFR2 in the liver senses excess iron, TFR2 in the bone marrow has the opposite role of sensing iron-deficiency. This would explain why the effect of lack of TFR2 shedding is not evident in TFR2-hemochromatosis where irondeficiency is never achieved(6), (15) . 
SUPPLEMENTARY DATA SUPPLEMENTARY METHODS
Constructs
The whole furin and Erythropoietin receptor (EPOR) open reading frame were amplified from human cDNA and cloned in pcDNA3.1 (+) (Invitrogen, Carlsbad, CA), as described(1, 2); PCSK7 construct was purchased from Origene (Origene Technologies, Rockville, MD). Rabbit PrlR construct is as described(3).
Cell culture conditions
HeLa, HEK293 and the hepatoma cell lines HuH7 (kindly provided by Martina 
SUPPLEMENTARY RESULTS
Diferric transferrin and not iron modulates TFR2 shedding
To evaluate whether modulation of cellular iron status might regulate TFR2 shedding HeLa cells were transiently transfected with wild type TFR2 coding vector (TFR2 WT ), and treated with the iron chelator deferoxamine (DFO, 100µM) or the iron donor ferric ammonium citrate (FAC, 100 µM plus Ascorbic Acid, 100 µM) or human diferric transferrin (H-holo-TF, 0.5-5 µM). The shedding was inhibited only in cells treated with holo-TF ( Figure S1A ) and the inhibition was dose dependent ( Figure   S1B ).
Searching for the protease responsible for TFR2 shedding
In order to identify the protease responsible for TFR2 shedding we tested different protease inhibitors. We observed a strong decrease of TFR2 shedding only after the pro-convertases inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethylketone (CMK, Alexis Biochemicals) treatment.
Among proconvertases involved in shedding soluble forms of proteins with relevant roles in iron metabolism PCSK7, a member of the family of furin-like pro-convertases has been recently shown to shed TFR1(7) and furin, activated in iron deficiency(1), is responsible for sHJV release(1), (8) .
We excluded as candidates for TFR2 shedding both PCSK7 and furin since their overexpression did not modify sTFR2 release (Fig. S3A) . Moreover, we observed that the consensus cleavage site for PCSK7 is not conserved in TFR2 (Fig. S3B) . holo-TF interference with gel migration of concentrated culture media, we pulleddown sTFR2 using anti-FLAG Sepharose-beads taking advantage of the FLAG tag at the C-terminus. As shown in Figure 2A , human holo-TF inhibits the release of sTFR2 in a dose-dependent manner. Anti-FLAG antibody was used to detect TFR2. Eighteen hours later luciferase activity was detected as described in Material and
SUPPLEMENTARY LEGEND TO FIGURES
Methods. sTFR2* causes a significant inhibitory effect on hepcidin promoter even in presence of the strong activator BMP6.
The experiments were performed three times in triplicate. Statistical significance is indicated above the bars: * = p< 0.05; ** = p< 0.005. 
